Search

Omeros Corp

Suletud

SektorTervishoid

19.71 3.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.34

Max

19.14

Põhinäitajad

By Trading Economics

Sissetulek

-38M

13M

Müük

19M

29M

P/E

Sektori keskmine

15.492

47.946

Aktsiakasum

0.02

Kasumimarginaal

46.381

Töötajad

175

EBITDA

-40M

18M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+46.67% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

12. nov 2026

Turustatistika

By TradingEconomics

Turukapital

385M

1.4B

Eelmine avamishind

16.14

Eelmine sulgemishind

19.71

Uudiste sentiment

By Acuity

21%

79%

39 / 340 Pingereas Healthcare

Omeros Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. okt 2026, 20:07 UTC

Omeros Corp shares are declining, reaching their lowest point mid-morning and finishing well below the 20-day moving average amid weaker overall market performance.

5. okt 2026, 20:06 UTC

Omeros Corp is advancing, reflecting a gain from Friday's close, despite pulling back from an earlier session high.

2. okt 2026, 21:01 UTC

Omeros Corp is trading lower in after-market hours, continuing a downward trend that has lasted for six consecutive sessions.

1. okt 2026, 22:15 UTC

Omeros Corp is trading modestly higher in after-market hours following five consecutive sessions of declines, despite mixed signals in the broader market.

30. sept 2026, 19:46 UTC

Omeros Corp shares fell modestly Wednesday, continuing a decline observed over the past three trading days, despite remaining above the 20-day moving average.

28. sept 2026, 20:07 UTC

Omeros Corp shares are declining, following a broader market trend, after peaking early in the session and reaching a low before the close.

24. sept 2026, 19:35 UTC

Omeros Corp shares fell sharply after an earlier gain, despite remaining above the 20-day moving average and near the upper end of its one-month range.

23. sept 2026, 23:02 UTC

Omeros Corp's stock declined in after-market trading, dropping from Wednesday's close despite remaining above its 20-day moving average.

22. sept 2026, 20:02 UTC

News
Social Media

Omeros shares advance sharply after Cantor Fitzgerald upgraded the stock to Overweight, citing strong Yartemlea launch and reinstating a $22 price target.

21. sept 2026, 19:16 UTC

Omeros Corp has advanced during Monday's trading session, reaching a notable peak earlier in the day while remaining below its 20-day moving average.

18. sept 2026, 20:13 UTC

Omeros Corp's shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

17. sept 2026, 20:08 UTC

Omeros Corp is advancing sharply in Thursday's trading, having risen as much as 7% earlier before pulling back slightly, reflecting strong overall market gains.

16. sept 2026, 19:36 UTC

Omeros Corp is trading higher, having peaked earlier in the day, though it remains below its 20-day moving average amid a broader trend of lower closes.

15. sept 2026, 20:51 UTC

Omeros Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures and elevated crude oil prices.

14. sept 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10. sept 2026, 20:03 UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

3. sept 2026, 19:46 UTC

Omeros Corp shares are higher today, supported by a modest upward trend since Wednesday. Easing Treasury yields may contribute to positive market sentiment.

2. sept 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, continuing a downward trend. No specific company news was identified to explain the movement.

1. sept 2026, 19:16 UTC

Omeros Corp shares are lower today, reflecting a decline since Monday's close amid rising global bond yields and inflationary pressures.

31. aug 2026, 23:16 UTC

Omeros Corp shares are higher in after-market trading. No specific news was identified to explain this movement, which appears independent of broader market trends.

28. aug 2026, 20:07 UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27. aug 2026, 22:01 UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26. aug 2026, 23:06 UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25. aug 2026, 23:12 UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21. aug 2026, 19:16 UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20. aug 2026, 23:32 UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19. aug 2026, 22:51 UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18. aug 2026, 23:16 UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17. aug 2026, 23:06 UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15. aug 2026, 00:01 UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Omeros Corp Prognoos

Hinnasiht

By TipRanks

46.67% tõus

12 kuu keskmine prognoos

Keskmine 27.5 USD  46.67%

Kõrge 33 USD

Madal 22 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Omeros Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

39 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.